Recombinant Human Erythropoietin Alfa Injection Franchise in Ahmedabad

Recombinant Human Erythropoietin Alfa Injection Supplier in Mumbai

Recombinant Human Erythropoietin Alfa Injection Distributor in Delhi

Anemia Management Injection Franchise Opportunity in Bangalore

Recombinant Human Erythropoietin Alfa Injection Stockist in Hyderabad
Recombinant Human Erythropoietin Alfa Injection Export & Manufacturing in Chandigarh

Home/Products /recombinant-human-erythropoietin-alfa-4000iu-injection

Recobent 4k Injection

Composition : Recombinant Human Erythropoietin Alfa (4000IU) Injection

Dosage Form : Injection

Packaging Type : Pre-Filled Syringe

Packaging : 1ml

Price : ₹0/-

Please Contact For Best Price

Recobent 4k Injection contains Recombinant Human Erythropoietin Alfa 4000 IU, a clinically proven erythropoiesis-stimulating agent used to treat anemia related to chronic kidney disease, chemotherapy, and other conditions involving reduced red blood cell production.

Recombinant Human Erythropoietin Alfa acts on bone marrow to stimulate red blood cell synthesis, helping improve hemoglobin levels and reduce the need for blood transfusions. This makes it an essential therapy in long-term anemia management.

The 4000 IU strength offers balanced dosing flexibility for both initiation and maintenance therapy. Its predictable response profile and acceptance in hospital and specialty care settings ensure steady demand.

Adding Recobent 4k Injection to your injectable and anemia care portfolio strengthens your range with a high-value, institution-driven product. Its strong prescriber trust, consistent usage, and export suitability make it an ideal choice for PCD pharma companies, distributors, and third-party manufacturing partners.

Read More

About the Product

Recobent 4k Injection contains Recombinant Human Erythropoietin Alfa 4000 IU, a clinically proven erythropoiesis-stimulating agent used to treat anemia related to chronic kidney disease, chemotherapy, and other conditions involving reduced red blood cell production.

Recombinant Human Erythropoietin Alfa acts on bone marrow to stimulate red blood cell synthesis, helping improve hemoglobin levels and reduce the need for blood transfusions. This makes it an essential therapy in long-term anemia management.

The 4000 IU strength offers balanced dosing flexibility for both initiation and maintenance therapy. Its predictable response profile and acceptance in hospital and specialty care settings ensure steady demand.

Adding Recobent 4k Injection to your injectable and anemia care portfolio strengthens your range with a high-value, institution-driven product. Its strong prescriber trust, consistent usage, and export suitability make it an ideal choice for PCD pharma companies, distributors, and third-party manufacturing partners.

Common side effects may include headache, increased blood pressure, fever, nausea, joint pain, or injection-site reactions. Rare but serious side effects include thromboembolic events or allergic reactions. Immediate medical attention is advised if severe or unusual symptoms occur.

Recobent 4K Injection is indicated for the treatment of anemia associated with chronic kidney disease, chemotherapy-induced anemia in cancer patients, anemia related to zidovudine therapy in HIV patients, and anemia due to certain chronic medical conditions, as prescribed by a healthcare professional.

Recobent 4K Injection should be administered only under medical supervision. Regular monitoring of hemoglobin levels and blood pressure is essential during therapy. Dosage and treatment duration must be decided by the treating physician.

Store Recobent 4K Injection at 2°C–8°C in a refrigerator. Do not freeze. Protect from light. Keep out of reach of children and do not use if the solution is cloudy or discolored.

Get in Touch